Want to see IXHL full AI Analyst Report?
Top Page
Incannex Healthcare Limited Sponsored ADR
(NASDAQ:IXHL)
Select Model
Select Model
Rating:45Neutral
Price Target:
$3.00
▲(1.69% Upside)
Action:Reiterated
Date:07/24/26
The score is held down primarily by weak financial performance (large ongoing losses and negative free cash flow) and bearish technical trends (below key moving averages with negative MACD). Offsetting these negatives, corporate events are notably positive—clinical momentum, strengthened IP, and non-dilutive funding—but they do not fully counter the current loss-making and cash-burn profile.
Positive Factors
Clinical advancement of lead asset IHL-42X
Commencing active Phase 2 screening materially de-risks development timing and data generation for IHL-42X. Durable impact: it advances regulatory interactions under FDA Fast Track, creates a clearer Phase III pathway, and strengthens the case for partnerships or licensing ahead of commercialization.
Negative Factors
Persistent negative operating and free cash flow
Sustained cash burn forces ongoing external financing or asset monetization to fund trials. Durable impact: constrains management flexibility, increases dilution or debt risk over time, and creates execution risk if future funding or milestone payments fall short of expectations.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical advancement of lead asset IHL-42X
Commencing active Phase 2 screening materially de-risks development timing and data generation for IHL-42X. Durable impact: it advances regulatory interactions under FDA Fast Track, creates a clearer Phase III pathway, and strengthens the case for partnerships or licensing ahead of commercialization.
Read all positive factors
Incannex Healthcare Limited Sponsored ADR (IXHL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$35.18M
Dividend YieldN/A
Average Volume (3M)229.06K
Price to Earnings (P/E)―
Beta (1Y)3.68
Revenue Growth-100.00%
EPS Growth54.21%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.29
Shares Outstanding11,964,554
10 Day Avg. Volume132,145
30 Day Avg. Volume229,058
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.55
Price to Sales (P/S)86.40
P/FCF Ratio-0.59
Enterprise Value/Market Cap-0.85
Enterprise Value/Revenue-451.35
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.66
Forecast
1Y Price Target
$18.00Price Target Upside510.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$40.00M
Incannex Healthcare Limited Sponsored ADR Business Overview & Revenue Model
Company Description
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. ...
How the Company Makes Money
null...
Incannex Healthcare Limited Sponsored ADR Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Sep 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.62K | 86.00K | 12.00K | 0.00 | 785.15K | 1.90M |
| Gross Profit | 0.00 | -160.00K | 12.00K | 0.00 | 778.79K | 987.02K |
| EBITDA | -45.51M | -23.54M | -27.70M | -20.39M | -16.54M | -11.34M |
| Net Income | -42.09M | -46.88M | -18.46M | -73.47M | -14.90M | -11.39M |
Balance Sheet | ||||||
| Total Assets | 75.01M | 20.45M | 17.05M | 35.80M | 38.01M | 9.32M |
| Cash, Cash Equivalents and Short-Term Investments | 68.90M | 15.04M | 5.86M | 33.29M | 37.50M | 9.12M |
| Total Debt | 163.00K | 258.00K | 373.00K | 784.16K | 0.00 | 0.00 |
| Total Liabilities | 1.60M | 7.06M | 5.83M | 4.45M | 2.02M | 754.62K |
| Stockholders Equity | 73.41M | 13.39M | 11.22M | 31.34M | 36.00M | 8.59M |
Cash Flow | ||||||
| Free Cash Flow | -10.24M | -12.52M | -16.12M | -16.65M | -12.85M | -6.91M |
| Operating Cash Flow | -10.23M | -12.51M | -15.85M | -16.18M | -12.85M | -6.87M |
| Investing Cash Flow | 20.00K | -8.00K | -277.00K | -475.61K | 0.00 | 29.32K |
| Financing Cash Flow | 84.52M | 21.40M | 0.00 | 12.30M | 41.18M | 12.33M |
Incannex Healthcare Limited Sponsored ADR Technical Analysis
Neutral
2.95
Price Trends
3.33
Negative
3.48
Negative
6.62
Negative
Market Momentum
-0.10
Negative
49.15
Neutral
81.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IXHL, the sentiment is Neutral. The current price of 2.95 is below the 20-day moving average (MA) of 3.08, below the 50-day MA of 3.33, and below the 200-day MA of 6.62, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 49.15 is Neutral, neither overbought nor oversold. The STOCH value of 81.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IXHL.
Incannex Healthcare Limited Sponsored ADR Risk Analysis
Incannex Healthcare Limited Sponsored ADR disclosed 68 risk factors in its most recent earnings report. Incannex Healthcare Limited Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Incannex Healthcare Limited Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $38.61M | -3.52 | -92.69% | ― | ― | 37.68% | |
47 Neutral | $30.74M | -0.75 | 4092.98% | ― | ― | 16.33% | |
46 Neutral | $35.95M | -2.80 | -52.86% | ― | -100.00% | 63.20% | |
45 Neutral | $35.18M | -1.31 | -92.47% | ― | -100.00% | 54.21% | |
41 Neutral | $19.98M | -0.39 | -217.27% | ― | ― | -74.39% |
* Healthcare Sector Average
IXHL
Incannex Healthcare Limited Sponsored ADR
3.16
-10.24
-76.45%
VERU
Veru
2.33
-1.26
-35.10%
NNVC
NanoViricides
1.42
-0.12
-7.79%
LEXX
Lexaria Bioscience
5.27
-7.05
-57.23%
SKYE
Skye Bioscience
0.52
-2.99
-85.21%
CALC
CalciMedica
0.69
-2.07
-75.11%
Incannex Healthcare Limited Sponsored ADR Corporate Events
Business Operations and StrategyProduct-Related Announcements
Incannex Begins Phase 2 DReAMzz Screening for IHL-42X
Positive
Jul 23, 2026
On July 23, 2026, Incannex Healthcare said it has begun screening participants in its DReAMzz Phase 2 dose confirmation study of IHL-42X for obstructive sleep apnea, after securing approvals for its first wave of clinical sites. The move signals a...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Incannex Secures Key U.S. Patent for IHL-42X
Positive
Jun 25, 2026
On June 25, 2026, Incannex announced that the U.S. Patent and Trademark Office granted a key patent covering the composition and treatment methods for its lead obstructive sleep apnoea candidate IHL-42X, with a baseline expiry of July 9, 2040. The...
Business Operations and StrategyStock BuybackFinancial DisclosuresPrivate Placements and Financing
Incannex Healthcare Secures Major Non-Dilutive R&D Funding
Positive
Jun 10, 2026
On June 10, 2026, Incannex Healthcare Inc. reported it had received A$6.04 million under the Australian Government’s Research and Development Tax Incentive Program, with a further approximately A$5.1 million expected later in 2026. The compa...
Business Operations and Strategy
Incannex Healthcare Gains Independent Buy-Rated Research Coverage
Positive
Jun 9, 2026
On June 9, 2026, Incannex Healthcare Inc. announced that Alliance Global Partners has initiated independent equity research coverage on the company, marking a notable step in raising its profile among investors. The report, dated June 8, 2026 and ...
Business Operations and StrategyProduct-Related Announcements
Incannex Launches DReAMzz Study for IHL-42X Sleep Apnea
Positive
May 14, 2026
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company listed on Nasdaq, develops combination therapies for high-impact chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. Its...
Business Operations and StrategyProduct-Related Announcements
Incannex Wins MedTech Award for IHL-42X Sleep Therapy
Positive
May 12, 2026
On May 12, 2026, Incannex Healthcare Inc. announced that it had won the “Best New Technology Solution for Drug Development” award at the 10th annual MedTech Breakthrough Awards, recognizing its lead candidate IHL-42X for obstructive sl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.